Neutrophils can strongly influence disease activity in cancer and in chronic inflammation. Here， we report for the first time the construction and characterization of antibody-fusion proteins featuring granulocyte-colony stimulating factor and interleukin-3 as payloads capable of enhancing neutrophil activity and a novel antibody-interleukin-4 fusion protein with neutrophil inhibitory potential. We used the F8 antibody specific to the alternatively-spliced extra domain A (EDA) of fibronectin as a targeting agent， since the cognate antigen is strongly upregulated in diseases characterized by angiogenesis. The fusion proteins GCSF-F8， F8-IL3 and F8-IL4-F8， were cloned， expressed， and their targeting a... More
Neutrophils can strongly influence disease activity in cancer and in chronic inflammation. Here， we report for the first time the construction and characterization of antibody-fusion proteins featuring granulocyte-colony stimulating factor and interleukin-3 as payloads capable of enhancing neutrophil activity and a novel antibody-interleukin-4 fusion protein with neutrophil inhibitory potential. We used the F8 antibody specific to the alternatively-spliced extra domain A (EDA) of fibronectin as a targeting agent， since the cognate antigen is strongly upregulated in diseases characterized by angiogenesis. The fusion proteins GCSF-F8， F8-IL3 and F8-IL4-F8， were cloned， expressed， and their targeting ability assessed， exhibiting preferential tumor uptake with tumor:blood ratios at 24 h after injection of 3.3， 18.2 and 27.3， respectively. In F9 tumor bearing-mice GCSF-F8 and F8-IL3 did not provide a therapeutic benefit， while F8-IL4-F8 showed a potent tumor growth retardation. In the collagen-induced model of arthritis， GCSF-F8 and F8-IL3 induced a worsening of the disease， while F8-IL4-F8 slowed arthritis progression but， surprisingly， exhibited substantial toxicity when used in combination with dexamethasone. Collectively， the results indicate that the novel fusion proteins could be expressed and efficiently delivered to the site of disease. However， they were not superior to other antibody-cytokine fusions previously described by our laboratory.
